Price
Target price
€14.65
€14.65
0.140%
0.02
0.140%
€39.65
09:58 / Tradegate
WKN: A2AG6H / Symbol: NTLA / Name: Intellia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Intellia Therapeutics Inc Stock
The Intellia Therapeutics Inc stock is trending slightly upwards today, with an increase of €0.020 (0.140%) compared to yesterday's price.
With 22 Buy predictions and 3 Sell predictions Intellia Therapeutics Inc is one of the favorites of our community.
With a target price of 39 € there is potential for a 166.21% increase which would mean more than doubling the current price of 14.65 € for Intellia Therapeutics Inc.
So far the community has only identified positive things for Intellia Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | 0.140% | 48.830% | 63.063% | -25.357% | 28.729% | -74.767% | -22.736% |
| Chromadex Corp | 0.000% | 4.938% | 1.190% | 168.987% | 65.049% | 521.572% | 141.477% |
| Polynovo Ltd | -7.560% | -4.972% | 52.212% | -41.096% | -28.926% | -11.340% | -34.848% |
| Cardio3 Biosciences S.A. | - | -0.366% | -25.069% | 29.524% | -58.850% | -84.038% | -96.613% |
Comments
Intellia Therapeutics (NASDAQ:NTLA) had its price target raised by analysts at HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Royal Bank Of Canada from $25.00 to $21.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at HC Wainwright from $30.00 to $25.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
News
Intellia (NTLA) Q2 Revenue Jumps 106%
Intellia Therapeutics (NASDAQ:NTLA), a biotechnology company developing CRISPR-based gene-editing therapies, reported second quarter 2025 results on August 7, 2025. The headline news was a
Analysts Think These Stocks Could More Than Double in Value
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more
